First Financial Corp IN lessened its holdings in shares of Allergan plc (NYSE:AGN) by 10.9% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 4,338 shares of the company’s stock after selling 529 shares during the quarter. First Financial Corp IN’s holdings in Allergan were worth $730,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of the stock. Liberty Wealth Management LLC grew its holdings in Allergan by 35.3% during the second quarter. Liberty Wealth Management LLC now owns 257 shares of the company’s stock valued at $43,000 after purchasing an additional 67 shares during the last quarter. TRUE Private Wealth Advisors grew its holdings in Allergan by 4.5% during the third quarter. TRUE Private Wealth Advisors now owns 1,715 shares of the company’s stock valued at $288,000 after purchasing an additional 74 shares during the last quarter. Patriot Financial Group Insurance Agency LLC grew its holdings in Allergan by 43.1% during the second quarter. Patriot Financial Group Insurance Agency LLC now owns 259 shares of the company’s stock valued at $44,000 after purchasing an additional 78 shares during the last quarter. Reilly Financial Advisors LLC grew its holdings in Allergan by 129.3% during the third quarter. Reilly Financial Advisors LLC now owns 172 shares of the company’s stock valued at $29,000 after purchasing an additional 97 shares during the last quarter. Finally, Nwam LLC grew its holdings in Allergan by 2.1% during the third quarter. Nwam LLC now owns 4,888 shares of the company’s stock valued at $823,000 after purchasing an additional 99 shares during the last quarter. 80.52% of the stock is currently owned by hedge funds and other institutional investors.

AGN traded up $0.31 during trading on Wednesday, reaching $170.47. 380,355 shares of the company’s stock were exchanged, compared to its average volume of 2,341,992. Allergan plc has a fifty-two week low of $114.27 and a fifty-two week high of $192.69. The company has a quick ratio of 0.91, a current ratio of 1.03 and a debt-to-equity ratio of 0.34. The business has a 50 day moving average price of $165.45 and a 200 day moving average price of $152.11. The company has a market capitalization of $55.82 billion, a P/E ratio of 10.21, a PEG ratio of 2.00 and a beta of 1.65.

Allergan (NYSE:AGN) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $4.38 earnings per share for the quarter, topping the Zacks’ consensus estimate of $4.34 by $0.04. Allergan had a negative net margin of 54.25% and a positive return on equity of 8.73%. The firm had revenue of $4.09 billion for the quarter, compared to the consensus estimate of $3.93 billion. During the same quarter in the previous year, the company earned $4.42 earnings per share. The business’s revenue was down .8% compared to the same quarter last year. As a group, research analysts forecast that Allergan plc will post 16.68 EPS for the current year.

Several equities analysts have commented on AGN shares. TheStreet upgraded Allergan from a “d+” rating to a “c” rating in a report on Friday, July 12th. Guggenheim downgraded shares of Allergan from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 7th. Svb Leerink restated a “market perform” rating and issued a $188.00 price objective (down previously from $217.00) on shares of Allergan in a research note on Thursday, July 18th. JPMorgan Chase & Co. set a $200.00 price objective on shares of Allergan and gave the stock a “buy” rating in a research note on Wednesday, June 19th. Finally, Mizuho downgraded shares of Allergan from a “buy” rating to a “neutral” rating and raised their price objective for the stock from $171.00 to $188.00 in a research note on Wednesday, June 26th. One investment analyst has rated the stock with a sell rating, sixteen have given a hold rating and six have assigned a buy rating to the company’s stock. Allergan has an average rating of “Hold” and an average price target of $179.15.

Allergan Company Profile

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.

Recommended Story: What is basic economics?

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.